Want to see BIOA full AI Analyst Report?
Top Page
BioAge Labs, Inc.
(NASDAQ:BIOA)
Select Model
Select Model
Rating:44Neutral
Price Target:
$6.50
▼(-35.71% Downside)
Action:Reiterated
Date:10/03/26
Overall score is weighed down primarily by weak financial performance (large losses and significant ongoing cash burn) and a strongly bearish technical setup (price below all major moving averages with negative momentum). These risks are partially offset by a solid balance sheet with very low leverage, while valuation signals are constrained by negative earnings and no dividend yield provided.
Positive Factors
Revenue Growth
Revenue growth and early commercialization provide evidence that BioAge is beginning to build a business beyond pure discovery. Although the base remains small, continued top-line expansion could improve operating leverage and support broader development investment over the next several quarters.
Negative Factors
Deep Operating Losses
The company’s revenue base remains far too small to absorb its research and operating costs, producing substantial ongoing losses. Unless revenue scales materially or spending becomes more efficient, persistent negative margins could continue eroding equity and constrain long-term strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
Revenue growth and early commercialization provide evidence that BioAge is beginning to build a business beyond pure discovery. Although the base remains small, continued top-line expansion could improve operating leverage and support broader development investment over the next several quarters.
Read all positive factors
BioAge Labs, Inc. (BIOA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$290.99M
Dividend YieldN/A
Average Volume (3M)768.79K
Price to Earnings (P/E)―
Beta (1Y)1.72
Revenue Growth168.06%
EPS Growth-6.76%
CountryUS
Employees61
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.38
Shares Outstanding45,896,908
10 Day Avg. Volume981,252
30 Day Avg. Volume768,788
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)1.75
Price to Sales (P/S)52.85
P/FCF Ratio-5.77
Enterprise Value/Market Cap2.69
Enterprise Value/Revenue75.62
Enterprise Value/Gross Profit76.09
Enterprise Value/Ebitda-8.34
Forecast
1Y Price Target
$32.56Price Target Upside222.01% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)-2.43
Revenue Forecast (FY)$7.62M
BioAge Labs, Inc. Business Overview & Revenue Model
Company Description
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insig...
BioAge Labs, Inc. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
72
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 10.36M | 8.99M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 10.29M | 8.99M | 0.00 | 0.00 | 0.00 |
| EBITDA | -93.93M | -79.69M | -68.58M | -55.90M | -39.35M |
| Net Income | -94.46M | -80.61M | -71.11M | -63.85M | -39.72M |
Balance Sheet | |||||
| Total Assets | 396.93M | 294.89M | 358.23M | 25.92M | 28.43M |
| Cash, Cash Equivalents and Short-Term Investments | 318.75M | 281.10M | 354.35M | 21.64M | 27.64M |
| Total Debt | 2.83M | 5.56M | 8.70M | 53.25M | 2.47M |
| Total Liabilities | 22.02M | 22.84M | 35.11M | 199.32M | 140.99M |
| Stockholders Equity | 374.91M | 272.05M | 323.13M | -173.40M | -112.56M |
Cash Flow | |||||
| Free Cash Flow | -88.09M | -82.35M | -51.89M | -37.53M | -36.28M |
| Operating Cash Flow | -87.60M | -81.63M | -51.52M | -37.36M | -36.18M |
| Investing Cash Flow | -212.85M | -95.22M | -366.00K | -266.00K | -103.00K |
| Financing Cash Flow | 154.15M | 11.47M | 381.20M | 34.94M | 2.50M |
BioAge Labs, Inc. Technical Analysis
Negative
10.11
Price Trends
8.95
Negative
14.72
Negative
16.54
Negative
Market Momentum
-1.03
Negative
25.74
Positive
20.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BIOA, the sentiment is Negative. The current price of 10.11 is above the 20-day moving average (MA) of 7.28, above the 50-day MA of 8.95, and below the 200-day MA of 16.54, indicating a bearish trend. The MACD of -1.03 indicates Negative momentum. The RSI at 25.74 is Positive, neither overbought nor oversold. The STOCH value of 20.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BIOA.
BioAge Labs, Inc. Risk Analysis
BioAge Labs, Inc. disclosed 66 risk factors in its most recent earnings report. BioAge Labs, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioAge Labs, Inc. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | $631.22M | 4.80 | -57.40% | ― | 26.19% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
53 Neutral | $178.10M | -27.93 | -20.23% | ― | 20.89% | 40.71% | |
49 Neutral | $244.49M | -5.86 | -376.95% | ― | ― | ― | |
49 Neutral | $38.89M | -2.77 | -27.42% | ― | -100.00% | 95.90% | |
44 Neutral | $290.99M | -2.66 | -28.99% | ― | 168.06% | -6.76% |
* General Sector Average
BIOA
BioAge Labs, Inc.
6.34
0.84
15.27%
IRWD
Ironwood Pharma
3.82
2.34
158.11%
LFCR
Lifecore Biomedical
6.45
-0.16
-2.42%
SXTC
China SXT Pharmaceuticals
0.15
-17,399.85
-100.00%
DERM
Journey Medical Corp
6.31
-0.69
-9.86%
IXHL
Incannex Healthcare Limited Sponsored ADR
3.10
-9.15
-74.70%
BioAge Labs, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
BioAge Labs initiates Phase 2 trial for BGE-102
Positive
Oct 2, 2026
BioAge Labs announced that the first participant has been dosed in QUELL-DME, a randomized, controlled Phase 2 trial testing once-daily oral NLRP3 inhibitor BGE-102 in adults with diabetic macular edema. The roughly 180-subject study will compare ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.